Crenolanib - AROG Pharmaceuticals/Pfizer
Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besylate - AROG Pharmaceuticals/Pfizer; IND-112201Latest Information Update: 31 Jan 2025
At a glance
- Originator Pfizer
- Developer AROG Pharmaceuticals
- Class Amines; Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
- Phase II Glioblastoma
- No development reported Gastric cancer; Glioma; Oesophageal cancer
- Discontinued Non-small cell lung cancer; Soft tissue sarcoma; Systemic mastocytosis
Most Recent Events
- 07 Dec 2024 Adverse events and efficacy data from the phase II trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 02 Jul 2024 Chemical structure information added
- 18 Dec 2023 AROG Pharmaceuticals completes a phase II trial in Acute myeloid leukaemia in USA (NCT02400255)